Kevin joined RoslinCT in 2019 as Chief Operating Officer, where he oversaw the company’s growth from 50 to 220 staff, establishment of a new manufacturing facility and acquisition of the company’s commercial manufacturing licence from the MHRA. He has recently moved to the role of Chief Technology and Strategy Officer and is responsible for developing and enhancing the company’s services and capabilities by leading the technology vision and strategy.
Kevin has more than 20 years working within the biotech industry, with a focus on cell therapy development and manufacturing, specifically with pluripotent stem cells. Before joining RoslinCT, Kevin held positions in Operations, Quality, R&D and commercial development.
He has been in the Roslin family for over 16 years and played a key role in development of Roslin Cells’ clinical-grade pluripotent cell lines and GMP translation and manufacture of cell therapies for both pre-clinical and clinical development. More recently, as COO at Censo Biotechnologies, he established the operational capability for the European Bank for Induced Pluripotent Stem Cells and was responsible for Censo’s stem cell generation, genome editing and assay development operations for drug discovery.